Skip to main content
Premium Trial:

Request an Annual Quote

UBS Downgrades Affymetrix Stock, Raises Target Price

NEW YORK, Jan. 31 (GenomeWeb News) - UBS Warburg has downgraded shares in Affymetrix to a "neutral" rating from a "buy" rating, CBS MarketWatch reported today.

According to MarketWatch, UBS said Affymetrix's stock trades at a "significant, and in our opinion well deserved, premium" to its peers and is now fairly priced. UBS also raised its price target for the stock to $47 per share from $43 per share, MarketWatch said.


Affy last week reported a surge in fourth-quarter revenue and increases net earnings.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.